2015年 消化器癌シンポジウム 演題速報レポート 消化器癌治療の広場
2015年1月15日〜17日に米国サンフランシスコにて開催された2015年 消化器癌シンポジウム(2015 Gastrointestinal Cancers Symposium)より、大腸癌と胃癌の注目演題のレポートをお届けします。演題レポートの冒頭には“Expert's view”として、臨床研究の第一線で活躍する監修ドクターのコメントを掲載しています。
監修・コメント
このサイトは医療関係者の方々を対象に作成しています。必ずご利用規約に同意の上、ご利用ください。記事内容で取り上げた薬剤の効能・効果および用法・用量には、日本国内 で承認されている内容と異なるものが、多分に含まれていますのでご注意ください。
更新履歴
演題レポート
Abstract #1
経口METキナーゼ阻害剤AMG337の臨床活性：MET 増幅胃食道接合部癌・胃癌・食道癌成人患者における検討
Clinical Activity of AMG 337, A Highly Selective Oral MET Kinase Inhibitor, in Adult Patients with MET-amplified Gastroesophageal Junction, Gastric, or Esophageal Cancer
Eunice L Kwak, et al.
Abstract #2
進行胃食道腺癌 (GEC) に対するFOLFOX±MET阻害剤Onartuzumabの無作為化第II相試験
Randomized Phase II Study of FOLFOX ± the MET Inhibitor, Onartuzumab, in Advanced Gastroesophageal Adenocarcinoma (GEC)
Manish A. Shah, et al.
Abstract #3
KEYNOTE-012試験：抗PD-1モノクローナル抗体薬Pembrolizumab (MK-3475) による治療を受けた進行胃癌患者におけるPD-L1発現と臨床転帰の関連
Relationship Between PD-L1 Expression and Clinical Outcomes in Patients with Advanced Gastric Cancer Treated with the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) in KEYNOTE-012
Kei Muro , et al.
Abstract #232
α-フェトプロテイン (AFP) 高値の進行肝細胞癌患者に対する2nd-lineとしてのRamucirumab：無作為化第III相試験 (REACH試験)
Ramucirumab as Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Patients with Elevated α-Fetoprotein from the Randomized Phase III REACH Study
Andrew X. Zhu, et al.
Abstract #507
ビタミンDが切除不能進行・再発大腸癌の生存に及ぼす影響：CALGB/SWOG 80405 (Alliance試験)の結果
Vitamin D Status and Survival of Metastatic Colorectal Cancer Patients: Results from CALGB/SWOG 80405 (Alliance)
Kimmie Ng, et al.
Abstract #511
術前肝局所動注化学療法 (PHRAC) による大腸癌治癒切除術後の異時性肝転移の発現抑制：多施設共同前向き無作為化比較試験
Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) Reduces the Occurrence of Metachronous Liver Metastasis after Curative Colorectal Cancer Resection: A Prospective, Multi-center, Randomized Controlled Trial
Jianmin Xu, et al.
Abstract #512
RAISE: A Randomized, Double-blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with Metastatic Colorectal Carcinoma Progression During or Following First-line Combination Therapy with Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
Josep Tabernero, et al.
Abstract #513
切除不能進行・再発大腸癌に対するFamitinibの多施設共同無作為化二重盲検並行群間第II相試験
A Randomized Double-blind, Parallel-group, Placebo Controlled, Multi-center, Phase II Clinical Study of Famitinib in the Treatment of Advanced Metastatic Colorectal Cancer
Rui-hua Xu, et al.
Abstract #11
RAINBOW: A Global, Phase 3, Double-blind Study of Ramucirumab (RAM) Plus Paclitaxel (PTX) Versus Placebo (PL) + PTX in the Treatment of Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma Following Disease Progression on First-line Platinum- and Fluoropyrimidine-Containing Combination Therapy: An Age-Group Analysis
Kei Muro, et al.
Abstract #515
Influence of Adjuvant Pretreatment on Outcome of FIRE-3 (AIO KRK-0306): A Randomized Phase III Study of FOLFIRI Plus Cetuximab or Bevacizumab as First-line Treatment for Wild-type (WT) KRAS (exon 2) Metastatic Colorectal Cancer (mCRC) Patients
Sebastian Stintzing, et al.
Abstract #573
抗EGFR抗体薬治療を行った切除不能進行・再発大腸癌の予後に対して拡大BRAF 変異が与える臨床的影響：BREAC試験
Clinical Impact of Expanded BRAF Mutational Status on the Outcome for Metastatic Colorectal Cancer Patients with Anti-EGFR Antibody: An Analysis of the BREAC Trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics)
Kentaro Yamazaki, et al.
Abstract #582
EGFR陽性・KRAS exon 2野生型の日本人切除不能進行・再発大腸癌におけるCetuximabに起因した皮膚毒性とEGFR CA-SSR1 変異の関連：JACCRO CC-05/06 AR試験
Association of EGFR CA Simple Sequence Repeat 1 (CA-SSR1) Variant with Cetuximab (Cet) -induced Skin Toxicity (ST) in Japanese Metastatic Colorectal Cancer (mCRC) Patients (pts) with Overexpressed EGFR and KRAS exon 2 Wild-type (KRAS wt) (JACCRO CC-05/06 AR)
Wataru Ichikawa, et al.
Abstract #660
RAS 野生型切除不能進行・再発大腸癌に対する1st-lineとしてのmFOLFOX6 + PanitumumabまたはBevacizumab：RECISTを越えた腫瘍縮小効果
First-line Treatment with Modified FOLFOX6 (mFOLFOX6) + Panitumumab or Bevacizumab in Wild-type RAS Metastatic Colorectal Carcinoma: Tumor Response Outcomes Beyond RECIST
Fernando Rivera, et al.
Abstract #705
既治療のKRAS exon 2野生型切除不能進行・再発大腸癌に対するPanitumumab vs. Cetuximabの第III相試験 (ASPECCT試験) ：低マグネシウム血症の予後への影響
Randomized Phase 3 Study of Panitumumab vs Cetuximab in Chemorefractory Wild-type KRAS Exon 2 Metastatic Colorectal Cancer: Outcomes by Hypomagnesemia in ASPECCT
Timothy Price, et al.
Abstract #714
Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old ?
Jerome Martin-Babau, et al.
Abstract #732
KRAS 野生型の切除不能進行・再発大腸癌に対する2nd-lineとしてのIRIS + Panitumumabの第II相試験
A Phase II Trial of Panitumumab with Irinotecan and S-1 (IRIS) as Second-line Treatment in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Rai Shimoyama, et al.
 |
 |